Holen Sie sich die Stockscreener-App
10.70
0.87%
-0.095
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript - MSN
Intellia Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - 富途牛牛
Wells Fargo Maintains Overweight on Intellia, PT Down to $45 - AInvest
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - Yahoo Finance
Intellia Therapeutics stock price target lowered to $45 by Wells Fargo - Investing.com Canada
Leerink Partners lowers Intellia Therapeutics stock price target to $41 By Investing.com - Investing.com Canada
Intellia: HC Wainwright Keeps Buy Rating, Lowers PT to $25 from $30. - AInvest
Gene-Editing's Quiet Revolution: Why Intellia Therapeutics Could Redefine Rare Disease Investing - AInvest
INTELLIA THERAPEUTICS, INC. (NTLA) - MSN
Intellia (NTLA) Q2 Revenue Jumps 106% - AOL.com
Intellia Therapeutics Inc (NTLA) Q2 2025 Earnings Call Highlights: Strategic Advancements and Financial Resilience - GuruFocus
Intellia Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Intellia Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Intellia Therapeutics' Momentum in ATTR-CM and HAE Trials: A Catalyst-Driven Path to First-Time Commercial Success - AInvest
Intellia Therapeutics' Q2 2025: Key Contradictions in MERIT Trial Expansion, Cash Runway, and Clinical Study Timelines - AInvest
Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating - TipRanks
RBC Cuts Price Target on Intellia Therapeutics to $21 From $25, Keeps Outperform Rating - MarketScreener
Intellia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Intellia Therapeutics beats Q2 2025 forecasts - Investing.com India
Transcript : Intellia Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Intellia Therapeutics Announces Executive Retirement - TipRanks
Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com Australia
Intellia Therapeutics Announces Second Quarter 2025 Financial Re - GuruFocus
Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Net Loss $0.98 a Share, vs. FactSet Est of $1.02 Loss - MarketScreener
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $14.2M, vs. FactSet Est of $11.9M - MarketScreener
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Intellia Reports 98% HAE Attack Reduction in 3-Year Data, Accelerates Phase 3 Enrollment Across Programs - Stock Titan
Intellia Therapeutics shares rise 6.61% intraday as Wall Street recovers from Friday's selloff. - AInvest
How many analysts rate Intellia Therapeutics Inc. as a “Buy”Explosive returns - Jammu Links News
Is Intellia Therapeutics Inc. stock overvalued or undervaluedAchieve rapid wealth accumulation with smart picks - Jammu Links News
What are Intellia Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - Jammu Links News
What is Intellia Therapeutics Inc. company’s growth strategyTriple-digit return opportunities - Jammu Links News
Why is Intellia Therapeutics Inc. stock attracting strong analyst attentionUnmatched profit potential - Jammu Links News
When is Intellia Therapeutics Inc. stock expected to show significant growthDiscover market opportunities with expert help - Jammu Links News
What is the dividend policy of Intellia Therapeutics Inc. stockAccelerated financial growth - Jammu Links News
Does Intellia Therapeutics Inc. stock perform well during market downturnsMaximize gains with proven stock analysis - Jammu Links News
What makes Intellia Therapeutics Inc. stock price move sharplyUnlock daily market insights for better decisions - Jammu Links News
How does Intellia Therapeutics Inc. compare to its industry peersFree Predictions - Jammu Links News
What catalysts could drive Intellia Therapeutics Inc. stock higher in 2025Breakout portfolio performance - Jammu Links News
Intellia Therapeutics Offers Inducement Grants Amidst Employment Expansion Amidst Challenges in Financial Health and Business Performance - AInvest
Intellia Therapeutics Awards Inducement Grants to New Employees - AInvest
Crispr Therapeutics shares rise 1.18% after-hours following Intellia Therapeutics' inducement grants announcement. - AInvest
Price Action Confirms Reversal in Intellia Therapeutics Inc. TrendFast Exit and Entry Strategy Guide Offered - metal.it
NTLA Awards Inducement Grant Amid Employment Expansion - GuruFocus
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - AInvest
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Intellia Therapeutics Awards Inducement Grants to New Employees. - AInvest
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Expands Team with Strategic Stock Grants Worth 18,200 Shares - Stock Titan
Intellia Therapeutics shares fall 4.12% premarket ahead of Q2 2025 earnings call. - AInvest
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - GlobeNewswire
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN - The Globe and Mail
Leading CRISPR Pioneer Intellia Therapeutics Announces Q2 2025 Financial Results Date - Stock Titan
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates | NTLA Stock News - GuruFocus
3.75%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):